Measuring Spending Levels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Spending Levels
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and type of spending made in 2010 and planned for 2011.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 50-62

PAT and QbD


Figure 1: Benefits of process analytical technology (PAT) cited by survey respondents.
The survey also examined the degree to which newer technologies, such as those relevant for PAT and QbD, are being applied and to what extent do they influence purchasing decisions on equipment and machinery. The survey showed that 57.6% of respondents do not incorporate PAT into their manufacturing activities, and 42.4% do. For those companies that do incorporate PAT, the leading benefits were better process understanding (64.2% of respondents cited as such) and increased efficiency or reduced waste (60.4% of respondents) (see Figure 1). For those companies using PAT, half increased their spending on machinery and equipment related to PAT in 2010, and half did not. For 2011, for those companies using PAT, slightly more (53.7%) will increase spending on PAT-related applications. For those companies not using PAT, 37.5% said the benefits don't justify the costs, and 26.4% said they do not use PAT because PAT would require modifications to equipment and procedures.

Areas of spend


Figure 2: Areas of highest expenditures for equipment and machinery in 2010. API is active pharmaceutical ingredient.
2010 levels . Similar to spending trends in 2009, the survey showed that the areas of highest spending for equipment and machinery in 2010 were in solid-dosage manufacturing, parenteral/aseptic/sterile manufacturing, and manufacturing for biologic-based active pharmaceutical ingredients (APIs), although the distribution of that spending reflected less spending on equipment for manufacturing solid-dosage forms and more for biologic-based APIs. The survey showed that 24% of respondents spent the most on equipment and machinery in 2010 for the manufacturing of solid-dosage forms (24.0%), followed by biologic-based APIs (17.5%), and then parenterals (13.6%)(see Figure 2). In 2009, 31% spent the most for solid-dosage manufacturing equipment, 18.5% spent the most on parenteral/aseptic/sterile manufacturing, and 15.8% spent the most on biologic-based APIs (1).

The survey further examined spending habits in equipment categories. The results showed the following trends for those that increased spending or kept spending the same in 2010 compared with 2009:

  • 39.6% increased spending on solid-dosage equipment; 48.1% kept it the same
  • 35.9% of respondents increased spending on equipment and machinery for quality assurance/quality control; 50.4% kept it the same
  • 35.5% increased spending for finished product, high-potency/high-containment manufacturing; 69.4% kept it the same
  • 33.8% increased spending for biologic API manufacturing; 52.1% kept it the same
  • 33.3% increased spending for API, high-potency/high-containment manufacturing; 52.4% kept it the same
  • 31.2% increased spending for continuous processing technology, finished product; 54.5% kept it the same
  • 30.7% increased spending for parenteral/sterile/aseptic manufacturing; 56.8% kept it the same
  • 27.6% increased spending for chemical API manufacturing; 48.7% kept it the same
  • 11.9% increased spending for continuous processing technology; API 64.4% kept it the same


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here